Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
Top Cited Papers
- 7 January 2021
- journal article
- letter
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 384 (1), 80-82
- https://doi.org/10.1056/nejmc2032195
Abstract
We recently reported the results of a phase 1 trial of a messenger RNA vaccine, mRNA-1273, to prevent infection with SARS-CoV-2; those interim results covered a period of 57 days after the first vaccination.1,2 Here, we describe immunogenicity data 119 days after the first vaccination (90 days after the second vaccination) in 34 healthy adult participants in the same trial who received two injections of vaccine at a dose of 100 μg. The injections were received 28 days apart. The recipients were stratified according to age (18 to 55 years, 56 to 70 years, or ≥71 years), and the assays used have been described previously.1,2Keywords
This publication has 4 references indexed in Scilit:
- Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older AdultsThe New England Journal of Medicine, 2020
- An mRNA Vaccine against SARS-CoV-2 — Preliminary ReportThe New England Journal of Medicine, 2020
- Humoral Immune Response to SARS-CoV-2 in IcelandThe New England Journal of Medicine, 2020
- Convergent antibody responses to SARS-CoV-2 in convalescent individualsNature, 2020